Clinical Trial

Semaglutide for Smoking Cessation in Patients With Diabetes

Study acronym: GLP1-SC
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-07; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2026-05-05
Trial Details
NCT Number NCT07059377
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
Enrollment 100 participants
Start Date 2026-02-13
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-11